 | • レポートコード：QFJ1-4256 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、妊娠糖尿病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（インスリン、SGLT-2阻害薬、アルファ-グルコシダーゼ阻害薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・妊娠糖尿病治療の市場動向 ・企業の競争状況、市場シェア ・妊娠糖尿病治療の種類別市場規模と予測2016-2027（インスリン、SGLT-2阻害薬、アルファ-グルコシダーゼ阻害薬、その他） ・妊娠糖尿病治療の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局） ・妊娠糖尿病治療の北米市場規模2016-2027（アメリカ、カナダ） ・妊娠糖尿病治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・妊娠糖尿病治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・妊娠糖尿病治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・妊娠糖尿病治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Biocon Limited、Eli Lilly、Novo Nordisk、Boehringer Ingelheim GmbH、Sanofi S.A.、Sun Pharmaceutical Industries Limited、Merck、Novartis、Adocia、Peptron、AstraZeneca plc、Pfizer, Inc、Takeda Pharmaceutical Company Ltd、Abbott、Antares Pharma、INJEX Pharma AG、Daiichi Sankyo） ・結論 |
Gestational diabetes can be defined as a type of diabetes that affects pregnant women. It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby. However, there are possibilities that diabetes may return in the later stages of life as type II diabetes mellitus. It is the inability of insulin to absorb the sugars consumed as part of the meal. It may be caused due to insulin resistance in a woman s body because of increasing levels of placental hormones being produced to sustain the development of the fetus. This condition starts when the female body is not able to make and use required amounts of insulin needed in pregnancy, resulting in a build-up of sugar in the bloodstream causing hyperglycemia.
Market Analysis and Insights: Global Gestational Diabetes Treatment Market
The global Gestational Diabetes Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gestational Diabetes Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gestational Diabetes Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gestational Diabetes Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gestational Diabetes Treatment market.
Global Gestational Diabetes Treatment Scope and Market Size
Gestational Diabetes Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gestational Diabetes Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Insulin
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Biocon Limited
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Merck
Novartis
Adocia
Peptron
AstraZeneca plc
Pfizer, Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
INJEX Pharma AG
Daiichi Sankyo
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gestational Diabetes Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Insulin
1.2.3 SGLT-2 Inhibitors
1.2.4 Alpha-glucosidase Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Gestational Diabetes Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Gestational Diabetes Treatment Market Perspective (2016-2027)
2.2 Gestational Diabetes Treatment Growth Trends by Regions
2.2.1 Gestational Diabetes Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Gestational Diabetes Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Gestational Diabetes Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Gestational Diabetes Treatment Industry Dynamic
2.3.1 Gestational Diabetes Treatment Market Trends
2.3.2 Gestational Diabetes Treatment Market Drivers
2.3.3 Gestational Diabetes Treatment Market Challenges
2.3.4 Gestational Diabetes Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gestational Diabetes Treatment Players by Revenue
3.1.1 Global Top Gestational Diabetes Treatment Players by Revenue (2016-2021)
3.1.2 Global Gestational Diabetes Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Gestational Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Gestational Diabetes Treatment Revenue
3.4 Global Gestational Diabetes Treatment Market Concentration Ratio
3.4.1 Global Gestational Diabetes Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gestational Diabetes Treatment Revenue in 2020
3.5 Gestational Diabetes Treatment Key Players Head office and Area Served
3.6 Key Players Gestational Diabetes Treatment Product Solution and Service
3.7 Date of Enter into Gestational Diabetes Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gestational Diabetes Treatment Breakdown Data by Type
4.1 Global Gestational Diabetes Treatment Historic Market Size by Type (2016-2021)
4.2 Global Gestational Diabetes Treatment Forecasted Market Size by Type (2022-2027)
5 Gestational Diabetes Treatment Breakdown Data by Application
5.1 Global Gestational Diabetes Treatment Historic Market Size by Application (2016-2021)
5.2 Global Gestational Diabetes Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Gestational Diabetes Treatment Market Size (2016-2027)
6.2 North America Gestational Diabetes Treatment Market Size by Type
6.2.1 North America Gestational Diabetes Treatment Market Size by Type (2016-2021)
6.2.2 North America Gestational Diabetes Treatment Market Size by Type (2022-2027)
6.2.3 North America Gestational Diabetes Treatment Market Size by Type (2016-2027)
6.3 North America Gestational Diabetes Treatment Market Size by Application
6.3.1 North America Gestational Diabetes Treatment Market Size by Application (2016-2021)
6.3.2 North America Gestational Diabetes Treatment Market Size by Application (2022-2027)
6.3.3 North America Gestational Diabetes Treatment Market Size by Application (2016-2027)
6.4 North America Gestational Diabetes Treatment Market Size by Country
6.4.1 North America Gestational Diabetes Treatment Market Size by Country (2016-2021)
6.4.2 North America Gestational Diabetes Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Gestational Diabetes Treatment Market Size (2016-2027)
7.2 Europe Gestational Diabetes Treatment Market Size by Type
7.2.1 Europe Gestational Diabetes Treatment Market Size by Type (2016-2021)
7.2.2 Europe Gestational Diabetes Treatment Market Size by Type (2022-2027)
7.2.3 Europe Gestational Diabetes Treatment Market Size by Type (2016-2027)
7.3 Europe Gestational Diabetes Treatment Market Size by Application
7.3.1 Europe Gestational Diabetes Treatment Market Size by Application (2016-2021)
7.3.2 Europe Gestational Diabetes Treatment Market Size by Application (2022-2027)
7.3.3 Europe Gestational Diabetes Treatment Market Size by Application (2016-2027)
7.4 Europe Gestational Diabetes Treatment Market Size by Country
7.4.1 Europe Gestational Diabetes Treatment Market Size by Country (2016-2021)
7.4.2 Europe Gestational Diabetes Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Gestational Diabetes Treatment Market Size (2016-2027)
8.2 Asia-Pacific Gestational Diabetes Treatment Market Size by Type
8.2.1 Asia-Pacific Gestational Diabetes Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Gestational Diabetes Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Gestational Diabetes Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Gestational Diabetes Treatment Market Size by Application
8.3.1 Asia-Pacific Gestational Diabetes Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Gestational Diabetes Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Gestational Diabetes Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Gestational Diabetes Treatment Market Size by Region
8.4.1 Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Gestational Diabetes Treatment Market Size (2016-2027)
9.2 Latin America Gestational Diabetes Treatment Market Size by Type
9.2.1 Latin America Gestational Diabetes Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Gestational Diabetes Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Gestational Diabetes Treatment Market Size by Type (2016-2027)
9.3 Latin America Gestational Diabetes Treatment Market Size by Application
9.3.1 Latin America Gestational Diabetes Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Gestational Diabetes Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Gestational Diabetes Treatment Market Size by Application (2016-2027)
9.4 Latin America Gestational Diabetes Treatment Market Size by Country
9.4.1 Latin America Gestational Diabetes Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Gestational Diabetes Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gestational Diabetes Treatment Market Size (2016-2027)
10.2 Middle East & Africa Gestational Diabetes Treatment Market Size by Type
10.2.1 Middle East & Africa Gestational Diabetes Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Gestational Diabetes Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Gestational Diabetes Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Gestational Diabetes Treatment Market Size by Application
10.3.1 Middle East & Africa Gestational Diabetes Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Gestational Diabetes Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Gestational Diabetes Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Gestational Diabetes Treatment Market Size by Country
10.4.1 Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biocon Limited
11.1.1 Biocon Limited Company Details
11.1.2 Biocon Limited Business Overview
11.1.3 Biocon Limited Gestational Diabetes Treatment Introduction
11.1.4 Biocon Limited Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.1.5 Biocon Limited Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Gestational Diabetes Treatment Introduction
11.2.4 Eli Lilly Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Gestational Diabetes Treatment Introduction
11.3.4 Novo Nordisk Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.3.5 Novo Nordisk Recent Development
11.4 Boehringer Ingelheim GmbH
11.4.1 Boehringer Ingelheim GmbH Company Details
11.4.2 Boehringer Ingelheim GmbH Business Overview
11.4.3 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Introduction
11.4.4 Boehringer Ingelheim GmbH Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.4.5 Boehringer Ingelheim GmbH Recent Development
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Details
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Gestational Diabetes Treatment Introduction
11.5.4 Sanofi S.A. Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.5.5 Sanofi S.A. Recent Development
11.6 Sun Pharmaceutical Industries Limited
11.6.1 Sun Pharmaceutical Industries Limited Company Details
11.6.2 Sun Pharmaceutical Industries Limited Business Overview
11.6.3 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Introduction
11.6.4 Sun Pharmaceutical Industries Limited Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.6.5 Sun Pharmaceutical Industries Limited Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Gestational Diabetes Treatment Introduction
11.7.4 Merck Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Gestational Diabetes Treatment Introduction
11.8.4 Novartis Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.8.5 Novartis Recent Development
11.9 Adocia
11.9.1 Adocia Company Details
11.9.2 Adocia Business Overview
11.9.3 Adocia Gestational Diabetes Treatment Introduction
11.9.4 Adocia Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.9.5 Adocia Recent Development
11.10 Peptron
11.10.1 Peptron Company Details
11.10.2 Peptron Business Overview
11.10.3 Peptron Gestational Diabetes Treatment Introduction
11.10.4 Peptron Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.10.5 Peptron Recent Development
11.11 AstraZeneca plc
11.11.1 AstraZeneca plc Company Details
11.11.2 AstraZeneca plc Business Overview
11.11.3 AstraZeneca plc Gestational Diabetes Treatment Introduction
11.11.4 AstraZeneca plc Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.11.5 AstraZeneca plc Recent Development
11.12 Pfizer, Inc
11.12.1 Pfizer, Inc Company Details
11.12.2 Pfizer, Inc Business Overview
11.12.3 Pfizer, Inc Gestational Diabetes Treatment Introduction
11.12.4 Pfizer, Inc Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.12.5 Pfizer, Inc Recent Development
11.13 Takeda Pharmaceutical Company Ltd
11.13.1 Takeda Pharmaceutical Company Ltd Company Details
11.13.2 Takeda Pharmaceutical Company Ltd Business Overview
11.13.3 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Introduction
11.13.4 Takeda Pharmaceutical Company Ltd Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.13.5 Takeda Pharmaceutical Company Ltd Recent Development
11.14 Abbott
11.14.1 Abbott Company Details
11.14.2 Abbott Business Overview
11.14.3 Abbott Gestational Diabetes Treatment Introduction
11.14.4 Abbott Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.14.5 Abbott Recent Development
11.15 Antares Pharma
11.15.1 Antares Pharma Company Details
11.15.2 Antares Pharma Business Overview
11.15.3 Antares Pharma Gestational Diabetes Treatment Introduction
11.15.4 Antares Pharma Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.15.5 Antares Pharma Recent Development
11.16 INJEX Pharma AG
11.16.1 INJEX Pharma AG Company Details
11.16.2 INJEX Pharma AG Business Overview
11.16.3 INJEX Pharma AG Gestational Diabetes Treatment Introduction
11.16.4 INJEX Pharma AG Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.16.5 INJEX Pharma AG Recent Development
11.17 Daiichi Sankyo
11.17.1 Daiichi Sankyo Company Details
11.17.2 Daiichi Sankyo Business Overview
11.17.3 Daiichi Sankyo Gestational Diabetes Treatment Introduction
11.17.4 Daiichi Sankyo Revenue in Gestational Diabetes Treatment Business (2016-2021)
11.17.5 Daiichi Sankyo Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Gestational Diabetes Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Insulin
Table 3. Key Players of SGLT-2 Inhibitors
Table 4. Key Players of Alpha-glucosidase Inhibitors
Table 5. Key Players of Others
Table 6. Global Gestational Diabetes Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Gestational Diabetes Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Gestational Diabetes Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Gestational Diabetes Treatment Market Share by Regions (2016-2021)
Table 10. Global Gestational Diabetes Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Gestational Diabetes Treatment Market Share by Regions (2022-2027)
Table 12. Gestational Diabetes Treatment Market Trends
Table 13. Gestational Diabetes Treatment Market Drivers
Table 14. Gestational Diabetes Treatment Market Challenges
Table 15. Gestational Diabetes Treatment Market Restraints
Table 16. Global Gestational Diabetes Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Gestational Diabetes Treatment Market Share by Players (2016-2021)
Table 18. Global Top Gestational Diabetes Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gestational Diabetes Treatment as of 2020)
Table 19. Ranking of Global Top Gestational Diabetes Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Gestational Diabetes Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Gestational Diabetes Treatment Product Solution and Service
Table 23. Date of Enter into Gestational Diabetes Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Gestational Diabetes Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Gestational Diabetes Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Gestational Diabetes Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Gestational Diabetes Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Gestational Diabetes Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Gestational Diabetes Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Gestational Diabetes Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Gestational Diabetes Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Gestational Diabetes Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Gestational Diabetes Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Gestational Diabetes Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Gestational Diabetes Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Gestational Diabetes Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Gestational Diabetes Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Gestational Diabetes Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Gestational Diabetes Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Gestational Diabetes Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Gestational Diabetes Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Gestational Diabetes Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Gestational Diabetes Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Gestational Diabetes Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Gestational Diabetes Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Gestational Diabetes Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Gestational Diabetes Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Gestational Diabetes Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Gestational Diabetes Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Gestational Diabetes Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Gestational Diabetes Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Gestational Diabetes Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Gestational Diabetes Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Gestational Diabetes Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Gestational Diabetes Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Gestational Diabetes Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Gestational Diabetes Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Biocon Limited Company Details
Table 64. Biocon Limited Business Overview
Table 65. Biocon Limited Gestational Diabetes Treatment Product
Table 66. Biocon Limited Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 67. Biocon Limited Recent Development
Table 68. Eli Lilly Company Details
Table 69. Eli Lilly Business Overview
Table 70. Eli Lilly Gestational Diabetes Treatment Product
Table 71. Eli Lilly Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 72. Eli Lilly Recent Development
Table 73. Novo Nordisk Company Details
Table 74. Novo Nordisk Business Overview
Table 75. Novo Nordisk Gestational Diabetes Treatment Product
Table 76. Novo Nordisk Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 77. Novo Nordisk Recent Development
Table 78. Boehringer Ingelheim GmbH Company Details
Table 79. Boehringer Ingelheim GmbH Business Overview
Table 80. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Product
Table 81. Boehringer Ingelheim GmbH Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 82. Boehringer Ingelheim GmbH Recent Development
Table 83. Sanofi S.A. Company Details
Table 84. Sanofi S.A. Business Overview
Table 85. Sanofi S.A. Gestational Diabetes Treatment Product
Table 86. Sanofi S.A. Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 87. Sanofi S.A. Recent Development
Table 88. Sun Pharmaceutical Industries Limited Company Details
Table 89. Sun Pharmaceutical Industries Limited Business Overview
Table 90. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Product
Table 91. Sun Pharmaceutical Industries Limited Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 92. Sun Pharmaceutical Industries Limited Recent Development
Table 93. Merck Company Details
Table 94. Merck Business Overview
Table 95. Merck Gestational Diabetes Treatment Product
Table 96. Merck Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 97. Merck Recent Development
Table 98. Novartis Company Details
Table 99. Novartis Business Overview
Table 100. Novartis Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 101. Novartis Recent Development
Table 102. Adocia Company Details
Table 103. Adocia Business Overview
Table 104. Adocia Gestational Diabetes Treatment Product
Table 105. Adocia Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 106. Adocia Recent Development
Table 107. Peptron Company Details
Table 108. Peptron Business Overview
Table 109. Peptron Gestational Diabetes Treatment Product
Table 110. Peptron Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 111. Peptron Recent Development
Table 112. AstraZeneca plc Company Details
Table 113. AstraZeneca plc Business Overview
Table 114. AstraZeneca plc Gestational Diabetes Treatment Product
Table 115. AstraZeneca plc Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 116. AstraZeneca plc Recent Development
Table 117. Pfizer, Inc Company Details
Table 118. Pfizer, Inc Business Overview
Table 119. Pfizer, Inc Gestational Diabetes Treatment Product
Table 120. Pfizer, Inc Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 121. Pfizer, Inc Recent Development
Table 122. Takeda Pharmaceutical Company Ltd Company Details
Table 123. Takeda Pharmaceutical Company Ltd Business Overview
Table 124. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Product
Table 125. Takeda Pharmaceutical Company Ltd Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 126. Takeda Pharmaceutical Company Ltd Recent Development
Table 127. Abbott Company Details
Table 128. Abbott Business Overview
Table 129. Abbott Gestational Diabetes Treatment Product
Table 130. Abbott Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 131. Abbott Recent Development
Table 132. Antares Pharma Company Details
Table 133. Antares Pharma Business Overview
Table 134. Antares Pharma Gestational Diabetes Treatment Product
Table 135. Antares Pharma Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 136. Antares Pharma Recent Development
Table 137. INJEX Pharma AG Company Details
Table 138. INJEX Pharma AG Business Overview
Table 139. INJEX Pharma AG Gestational Diabetes Treatment Product
Table 140. INJEX Pharma AG Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 141. INJEX Pharma AG Recent Development
Table 142. Daiichi Sankyo Company Details
Table 143. Daiichi Sankyo Business Overview
Table 144. Daiichi Sankyo Gestational Diabetes Treatment Product
Table 145. Daiichi Sankyo Revenue in Gestational Diabetes Treatment Business (2016-2021) & (US$ Million)
Table 146. Daiichi Sankyo Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gestational Diabetes Treatment Market Share by Type: 2020 VS 2027
Figure 2. Insulin Features
Figure 3. SGLT-2 Inhibitors Features
Figure 4. Alpha-glucosidase Inhibitors Features
Figure 5. Others Features
Figure 6. Global Gestational Diabetes Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Gestational Diabetes Treatment Report Years Considered
Figure 11. Global Gestational Diabetes Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Gestational Diabetes Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Gestational Diabetes Treatment Market Share by Regions: 2020 VS 2027
Figure 14. Global Gestational Diabetes Treatment Market Share by Regions (2022-2027)
Figure 15. Global Gestational Diabetes Treatment Market Share by Players in 2020
Figure 16. Global Top Gestational Diabetes Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gestational Diabetes Treatment as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Gestational Diabetes Treatment Revenue in 2020
Figure 18. Global Gestational Diabetes Treatment Revenue Market Share by Type (2016-2021)
Figure 19. Global Gestational Diabetes Treatment Revenue Market Share by Type (2022-2027)
Figure 20. North America Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Gestational Diabetes Treatment Market Share by Type (2016-2027)
Figure 22. North America Gestational Diabetes Treatment Market Share by Application (2016-2027)
Figure 23. North America Gestational Diabetes Treatment Market Share by Country (2016-2027)
Figure 24. United States Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Gestational Diabetes Treatment Market Share by Type (2016-2027)
Figure 28. Europe Gestational Diabetes Treatment Market Share by Application (2016-2027)
Figure 29. Europe Gestational Diabetes Treatment Market Share by Country (2016-2027)
Figure 30. Germany Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Gestational Diabetes Treatment Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Gestational Diabetes Treatment Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Gestational Diabetes Treatment Market Share by Region (2016-2027)
Figure 40. China Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Gestational Diabetes Treatment Market Share by Type (2016-2027)
Figure 48. Latin America Gestational Diabetes Treatment Market Share by Application (2016-2027)
Figure 49. Latin America Gestational Diabetes Treatment Market Share by Country (2016-2027)
Figure 50. Mexico Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Gestational Diabetes Treatment Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Gestational Diabetes Treatment Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Gestational Diabetes Treatment Market Share by Country (2016-2027)
Figure 56. Turkey Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Gestational Diabetes Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Biocon Limited Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 60. Eli Lilly Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 61. Novo Nordisk Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 62. Boehringer Ingelheim GmbH Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 63. Sanofi S.A. Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 64. Sun Pharmaceutical Industries Limited Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 67. Adocia Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 68. Peptron Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 69. AstraZeneca plc Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 70. Pfizer, Inc Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 71. Takeda Pharmaceutical Company Ltd Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 72. Abbott Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 73. Antares Pharma Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 74. INJEX Pharma AG Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 75. Daiichi Sankyo Revenue Growth Rate in Gestational Diabetes Treatment Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
世界のインスリン非依存型糖尿病治療薬市場規模・現状・予測（2021年-2027年） Diabetes is a metabolic disease, wherein the body is either unable to secret insulin (type 1 diabetes) or is unable to utilize the generated insulin (type 2 diabetes). Market Analysis and Insights: Global Non Insulin Anti diabetes Drugs Market The global Non Insulin Anti diabetes Drugs market size i…- 糖尿病用非インスリン療法のグローバル市場調査 2019年 The global Non-Insulin Therapies for Diabetes market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Non-Insulin Therapies for Diabetes volume and value at global level, regional level and company level. F…
- 世界の糖尿病栄養市場規模・現状・予測（2021年-2027年） Diabetes nutrition products are dietary products that contain less sugar and carbohydrate content. Market Analysis and Insights: Global Diabetes Nutrition Market The global Diabetes Nutrition market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% duri…
- 世界の1型糖尿病治療市場規模・現状・予測（2021年-2027年） Type-1 diabetes accounts for 5%–10% of all diabetes cases worldwide. Failure to produce insulin is the cause of this type of diabetes. Market Analysis and Insights: Global Type-1 Diabetes Treatment Market The global Type-1 Diabetes Treatment market size is projected to reach US$ 7034.4 million by 2…
- 世界の糖尿病治療薬市場規模・現状・予測（2021年-2027年） Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications. Market Analysis and Insights: Global Diab…